Entacapone Augmentation for Schizophrenia

Not Applicable

Completed

• Conditions: Schizophrenia

• Registration Number: NCT00192855
• Lead Sponsor: Rambam Health Care Campus

Brief Summary

This study is testing the hypothesis that Entacapone added to ongoing antipsychotic treatment can be beneficial in schizophrenic patients with negative symptoms.

Detailed Description

Not available

Study Timeline

• Study Start: 2003-06
• Status Verified: 2005-09
• Study First Submitted: 2005-09-13
• Study First Submitted QC: 2005-09-14
• Study First Posted: 2005-09-19
• Primary Completion: 2006-10
• Study Completion: 2006-10
• Last Update Submitted: 2010-08-24
• Last Update Posted: 2010-08-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 52

Inclusion Criteria

• predominantly negative symptoms
• stable on ongoing antipsychotic treatment

Read More

Exclusion Criteria

• acute psychotic exacerbation
• suicidal ideation
• uncontrolled systemic disease

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: FACTORIAL

Primary Outcome Measures

Name	Time	Method
Improvement in specific rating scales during the study and after completion, compared to baseline.	Baseline and once a month untill end of study

Secondary Outcome Measures

Name	Time	Method
Change in PANSS score.	Before and after intervention

Trial Locations

Locations (1)

Rambam medical center; 🇮🇱 Haifa, Israel